• Jin-Ying Lu, Yi-Yao Chang, Ting-Wei Lee, Ming-Hsien Wu, Zheng-Wei Chen, Yen-Ta Huang, Tai-Shuan Lai, Leay Kiaw Er, Yen-Hung Lin, Vin-Cent Wu, Hao-Min Cheng, Hsien-Li Kao, Jia-Yin HouCharlesCCardiovascular Center, MacKay Memorial Hospital, Taipei, Taiwan. Electronic address: jiayinhou@gmail.com., Kwan-Dun Wu, Szu-Tah Chen, and Feng-Hsuan Liu.
• Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: jinyinglu@ntuh.gov.tw.
• J Formos Med Assoc. 2024 Mar 1; 123 Suppl 2: S91S97S91-S97.

AbstractAnti-hypertensive medications may affect plasma renin activity and/or plasma aldosterone concentration, misleading the interpretation of the aldosterone-to-renin ratio when screening for primary aldosteronism. The Task Force of Taiwan PA recommends that, when necessary, using α-adrenergic receptor blocking agents, centrally acting α-adrenergic agonists, and/or non-dihydropyridine calcium channel blockers should be considered to control blood pressure before screening for PA. We recommend temporarily holding β-adrenergic receptor blocking agents, mineralocorticoid receptor antagonists, dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and all diuretics before screening for PA. Further large-scale randomized controlled studies are required to confirm the recommendations.Copyright © 2023 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.

23 keywords...

hide…